| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The non-labeled compound, 7-methylguanosine, is an inhibitor of cNIIIB nucleotidase, with an IC50 of 87.8 +/- 7.5 microM. It is an RNA modification involved in the cap structure of messenger RNA (mRNA), where it participates in the regulation of protein synthesis. The 7-methylguanosine cap at the 5' end of mRNA is recognized by the translation initiation factor eIF4E, facilitating ribosome binding and translation. It is also found in other RNA species like tRNA. As an internal standard, 7-Methylguanosine-d3 itself has no biological activity.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
The unlabeled 7-methylguanosine is a novel cNIIIB nucleotidase inhibitor. In vitro, it has been shown to have an IC50 value of 87.8 +/- 7.5 microM for cNIIIB, an enzyme involved in nucleotide metabolism. It also participates in RNA synthesis and modification processes, acting as a substrate for enzymes that recognize the 7-methylguanosine cap structure during mRNA capping and processing. Its ability to stabilize RNA structures and promote translation has been demonstrated. As an internal standard, the deuterated compound is not intended for in vivo activity assessment. Its purpose is analytical. |
| ln Vivo |
As an internal standard, the deuterated compound is not intended for in vivo activity assessment. The compound is a substrate for enzymes that recognize the 7-methylguanosine cap during mRNA capping and processing, and it plays a crucial role in stabilizing RNA structures and promoting translation. It can be used in RNA synthesis and modification processes.
|
| Enzyme Assay |
This compound is intended for use as an internal standard for the quantification of 7-methylguanosine by GC- or LC-MS. In this context, a fixed amount of the deuterated internal standard is spiked into biological samples (e.g., plasma, urine, cell lysates) at the start of sample preparation. The sample undergoes protein precipitation or solid-phase extraction (SPE), and the supernatant is analyzed by LC-MS/MS. The deuterated internal standard and the non-labeled analyte are detected in multiple reaction monitoring (MRM) mode, and the peak area ratio is used for quantification. This approach provides high precision and accuracy in bioanalytical methods.
|
| Cell Assay |
7-Methylguanosine-d3 is used as an internal standard for the quantification of 7-methylguanosine by GC- or LC-MS in cellular extracts and biological fluids. The assay involves lysing cells or homogenizing tissues, followed by protein precipitation with an organic solvent such as acetonitrile or methanol. After centrifugation, the supernatant is analyzed by LC-MS/MS. A fixed amount of the deuterated internal standard is added to all samples (standards, QCs, and unknowns) at the beginning of the extraction process to correct for matrix effects and recovery losses. The peak area ratio of analyte to internal standard is plotted against nominal concentration to construct a calibration curve.
|
| Animal Protocol |
The internal standard is not administered in animal studies. Instead, it is a critical reagent used to analyze samples collected from animal models. Following the administration of other compounds or experimental drugs that may affect RNA metabolism, plasma or tissue samples from rodents or other animals are collected. The d3-internal standard is spiked into these samples before LC-MS/MS analysis. This allows for the accurate measurement of endogenous 7-methylguanosine levels, which can serve as a biomarker for RNA turnover or cellular stress. The concentration of 7-methylguanosine in the samples is determined based on the peak area ratio.
|
| ADME/Pharmacokinetics |
The compound has a molecular weight of 301.29 and is a white to off-white solid powder. It is soluble in DMSO and methanol. For LC-MS/MS applications, it is typically dissolved in a suitable solvent such as water or methanol to prepare stock solutions. The deuterated compound (d3) is stable and has the same chemical properties as the non-labeled compound, allowing it to co-elute during chromatography while being distinguishable by mass spectrometry. Storage should be at -20degC, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
The labeled compound is non-toxic at the trace concentrations used for analytical purposes. The unlabeled compound, 7-methylguanosine, is a naturally occurring modified nucleoside. No significant toxicity has been reported. The compound is intended for research use only and is not for human therapeutic or diagnostic use. Standard laboratory safety precautions for handling fine chemicals apply.
|
| References |
|
| Additional Infomation |
7-Methylguanosine-d3 is a research-grade stable isotope-labeled chemical used as an internal standard for LC-MS/MS quantification. The unlabeled 7-methylguanosine is a methylated purine nucleoside that is an RNA modification. It is also a novel cNIIIB nucleotidase inhibitor with an IC50 of 87.8 +/- 7.5 microM. This product is for research use only and is not a clinical drug; it has no FDA approval for human therapy. It is used to study RNA metabolism and nucleotidase inhibition.
|
| Molecular Formula |
C11H13D3N5O5
|
|---|---|
| Molecular Weight |
301.29
|
| Related CAS # |
7-Methylguanosine;20244-86-4
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3191 mL | 16.5953 mL | 33.1906 mL | |
| 5 mM | 0.6638 mL | 3.3191 mL | 6.6381 mL | |
| 10 mM | 0.3319 mL | 1.6595 mL | 3.3191 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
